Anzeige
Mehr »
Donnerstag, 04.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 856840 | ISIN: JP3201200007 | Ticker-Symbol: OLY1
Frankfurt
04.09.25 | 08:05
10,315 Euro
-0,10 % -0,010
Branche
Gesundheitswesen
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
OLYMPUS CORPORATION Chart 1 Jahr
5-Tage-Chart
OLYMPUS CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
10,30510,49520:48
10,38010,53520:06
PR Newswire
173 Leser
Artikel bewerten:
(1)

Olympus Corporation of the Americas: Olympus Announces Distribution Partnership with MacroLux Medical for Single-Use Urology Products

WESTBOROUGH, Mass., Sept. 4, 2025 /PRNewswire/ -- Olympus Corp., a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today an exclusive global distribution agreement with MacroLux Medical Technology Co., Ltd. to distribute single-use urology products.

Olympus Corp. announced a global distribution agreement with MacroLux Medical to distribute single-use urology products in the U.S. and Canada and in countries in Europe and the Asia Pacific region

The agreement includes multiple single-use cystoscopes, ureteroscopes and suction access sheaths. These devices are used to access and visualize the bladder and urinary tract to diagnose and treat urinary diseases and disorders such as kidney stones.

"We are excited to embark on this new partnership, a synergy that underscores our unwavering commitment to advancing patient care," said Gabriel McHugh, Executive Vice President Surgical and Interventional Solutions, Olympus Corp. "By integrating innovative single-use technology into our urology portfolio, we are enhancing the landscape of urological care for our customers and their patients."

Olympus delivers a broad range of kidney and bladder stone management and non-muscular invasive bladder cancer (NMIBC) visualization and access solutions for detection and treatment. With the addition of the MacroLux Medical single-use endoscopes and access sheath portfolio, Olympus can offer physicians increased flexibility and confidence in visualization and surgical precision.

"Olympus is a trusted endoscopy partner for treatment of urological disease and now is uniquely positioned to provide access to a broad range of high-quality endoscopes. This includes reusable and single-use flexible scopes, rigid and semi-rigid scopes, powerful lithotripsy solutions, and gold-standard NMIBC detection," said Glen Branconier, Senior Vice President & General Manager of Urology/Gynecology, Olympus Corp. "We are excited and privileged to provide urologists and health care providers with the tools they need to confidently care for their patients."

The agreement includes distribution in the United States, Canada, countries across Europe and countries in the Asia Pacific region. Countries in Europe include:

  • UK (England, Scotland, Wales and Northern Ireland)
  • Ireland
  • Austria
  • Belgium
  • Germany
  • Netherlands
  • Luxembourg
  • Norway
  • Denmark
  • Switzerland
  • Sweden

Countries/regions in the APAC region include:

  • Australia
  • New Zealand
  • Hong Kong, PRC
  • Singapore
  • South Korea

"Olympus is a highly respected industry leader that we deeply admire. Our strategic cooperation with Olympus generates powerful synergies, enabling us to combine our respective strengths and accelerate the market introduction of MacroLux's urological disposable endoscopes and access sheath solutions, products that offer clinical value," said Martin Zhang, Chief Executive Officer, MacroLux Medical. "These products may enhance clinical efficiency and help improve patient treatment outcomes. This collaboration also inspires us to continue with product innovation and R&D, delivering clinical solutions to customers worldwide."

The MacroLux single-use cystoscopes offer the following features:

  • 140° field of view

  • 235° up/145° down distal tip angulation

  • 14.4Fr outer diameter with 2.2mm working channel

The MacroLux single-use ureteroscopes offer the following features:

  • 7.5Fr and 8.25Fr outer diameter scope offering

  • 275° distal tip angulation

  • AutoHold Technology thumb lever control

  • 120° field of view

The MacroLux single-use suction access sheaths are available in multiple sizes to meet various urological procedure needs and negative pressure connection for stone removal.

These products may not be available in all regions. As with any medical device, careful consideration should be given to all applicable labeling, including potential risks and benefits associated with the product.

Visit the Olympus urology product page for more information about Olympus' complete urology portfolio.

About Olympus?
At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit olympus-global.com and follow our global LinkedIn and X accounts.

About MacroLux Medical
Headquartered in Shenzhen, China, MacroLux Medical Technology Co., Ltd. was established in October 2020. A medical technology company specializing in innovative solutions for disposable endoscopic diagnosis and treatment, the founding team hails from leading Chinese medical device companies and possesses more than a decade of experience in the research and development, global commercialization, and production management of endoscopes and minimally invasive surgical instruments. Committed to continuous innovation, MacroLux Medical aspires to provide disposable endoscopic diagnostic and therapeutic solutions worldwide, enabling earlier disease detection and enhanced patient treatment. For more information, visit microlite.cn.


Photo - https://mma.prnewswire.com/media/2764163/Olympus_MacroLux.jpg

Logo - https://mma.prnewswire.com/media/1774929/Olympus_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/olympus-announces-distribution-partnership-with-macrolux-medical-for-single-use-urology-products-302546653.html

© 2025 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.